Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Carboxymethylcellulose Clear all
Recruiting Phase 2 Interventional

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

NCT03606967
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Orange, California • Sacramento, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 26, 2026, 1:54 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Echothiophate Iodide for the Prevention of Progression of Myopia

NCT02544529
View directory record Official record
Conditions
Myopia
Interventions
Echothiophate Iodide 0.03% Ophthalmic Solution, Carboxymethylcellulose Sodium (0.5%)
Drug
Lead sponsor
Danbury Eye Physicians & Surgeons, PC
Other
Eligibility
9 Years to 15 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Danbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Sep 26, 2026, 1:54 AM EDT
Completed Not applicable Interventional

Changes in Tear Osmolarity Over Time With Sustained Use of TheraTears

NCT02100787
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
TheraTears lubricating drops
Other
Lead sponsor
Jenkins Eye Care
Other
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 26, 2026, 1:54 AM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 26, 2026, 1:54 AM EDT
Terminated Not applicable Interventional Results available

Radiosurgical Hypophysectomy for Bone Metasteses Pain

NCT03377517
View directory record Official record
Conditions
Bone Metastases
Interventions
radiosurgical hypophysectomy
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 26, 2026, 1:54 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Healing of Persistent Epithelial Defects

NCT02395952
View directory record Official record
Conditions
Cornea
Interventions
carboxymethylcellulose sodium, Acuvue Oasys Bandage Contact Lens, Ambiodisk, Prokera
Drug · Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Sep 26, 2026, 1:54 AM EDT
Not listed Phase 2 Interventional

Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome

NCT01544283
View directory record Official record
Conditions
Shoulder Pain
Interventions
Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch, Triamcinolone Acetonide
Drug
Lead sponsor
Injury Care Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Sep 26, 2026, 1:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Retention of an Orally Administered Device Using Gamma Scintigraphy

NCT00754091
View directory record Official record
Conditions
Healthy Subjects
Interventions
Polymer based lubricating liquid
Device
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 26, 2026, 1:54 AM EDT
Completed Not applicable Interventional Results available

Essential Voice Tremor: A Study of Botulinum Toxin Treatment and Injection Augmentation

NCT02711995
View directory record Official record
Conditions
Essential Tremor
Interventions
RenuGel, Botulinum Toxin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 26, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease

NCT02280473
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Refresh Optive® Gel Drops, REFRESH LIQUIGEL®
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Petaluma, California • San Diego, California • Bangor, Maine + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 26, 2026, 1:54 AM EDT
Recruiting Early Phase 1 Interventional

FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

NCT06472661
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Echopulse or Echopulse HD, PolyICLC
Device · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 26, 2026, 1:54 AM EDT
Withdrawn Phase 1 Interventional

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

NCT05457959
View directory record Official record
Conditions
Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis, Nivolumab, Placebo Administration, Poly ICLC, Resection
Biological · Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
13 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 26, 2026, 1:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

NCT02078648
View directory record Official record
Conditions
Adult Brain Glioblastoma, Glioblastoma Multiforme
Interventions
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF, Imiquimod
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 26, 2026, 1:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fluorophotometry Evaluation of Lubricant Eye Drops

NCT00347854
View directory record Official record
Conditions
Healthy
Interventions
Systane Free lubricant eye drops, Visine Tears Lubricant Eye Drops, Refresh Liquigel Lubricant Eye Drops, Refresh Plus Lubricant Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 26, 2026, 1:54 AM EDT
Completed Phase 4 Interventional Results available

Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial

NCT03080493
View directory record Official record
Conditions
Abortion, Induced, Cervical Preparation, Pain
Interventions
Gabapentin 600mg, Placebo oral capsule, acetaminophen/codeine and ibuprofen
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Sep 26, 2026, 1:54 AM EDT
Completed Not applicable Interventional Results available

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

NCT00932477
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear, Glycerin and Polysorbate 80 based artificial tear
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 26, 2026, 1:54 AM EDT
Terminated Phase 1 Interventional

A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

NCT05121948
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer, Transitional Cell Carcinoma of the Bladder, Other Solid Tumors, Clear Cell Renal Cell Carcinoma
Interventions
HC-7366
Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
La Jolla, California • Aurora, Colorado • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 26, 2026, 1:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab + Poly-ICLC in MRP Colon Cancer

NCT02834052
View directory record Official record
Conditions
Metastatic Colon Cancer, Solid Tumor
Interventions
pembrolizumab, Poly-ICLC
Drug
Lead sponsor
Asha Nayak
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 26, 2026, 1:54 AM EDT
Completed Early Phase 1 Interventional

MUC1 Vaccine for Triple-negative Breast Cancer

NCT00986609
View directory record Official record
Conditions
Breast Cancer, Inflammatory Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions
MUC-1 peptide vaccine, poly ICLC, MUC1 peptide-poly-ICLC adjuvant vaccine, laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
Biological · Other
Lead sponsor
Joseph Baar, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Sep 26, 2026, 1:54 AM EDT
Terminated Not applicable Interventional Results available

A Comparative Evaluation of a MPS Dressing and a CMC Dressing on Subjects With Lower Extremity Venous Ulcers

NCT03903692
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Marine polysaccharide dressing, Carboxymethylcellulose dressing
Device
Lead sponsor
Medline Industries
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Fresno, California • Selma, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 26, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

NCT04401579
View directory record Official record
Conditions
COVID-19
Interventions
Placebo, Remdesivir, Baricitinib
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 26, 2026, 1:54 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

NCT02951052
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), 2 NRTIs plus an INI, NNRTI, or PI
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 26, 2026, 1:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief

NCT02455050
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Sodium Based Eye Drops, Systane® Gel Drops, Genteal® Lubricant Gel Drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 26, 2026, 1:54 AM EDT
Withdrawn Not applicable Interventional

Sphenopalatine Ganglion Block for Postdural Puncture Headache in the Emergency Department

NCT02517931
View directory record Official record
Conditions
Postdural Puncture Headache
Interventions
Sphenopalatine Ganglion Block, Placebo
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 26, 2026, 1:54 AM EDT